|
|
||||||||
-receptor blockers in heart failure therapy
Cardiology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642
Submitted 18 August 2003 ; accepted in final form 19 April 2004
The present study was carried out to determine whether beneficial effects of carvedilol in congestive heart failure (CHF) are mediated via its
-adrenergic blocking, antioxidant, and/or
-adrenergic blocking action. Rabbits with heart failure induced by rapid cardiac pacing were randomized to receive subcutaneous carvedilol, metoprolol, propranolol plus doxazosin, or placebo pellets for 8 wk and compared with sham-operated rabbits without pacing. We found rapid cardiac pacing produced clinical heart failure, left ventricular dilation, and decline of left ventricular fractional shortening. This was associated with an increase in left ventricular end-diastolic pressure, decrease in left ventricular first derivative of left ventricular pressure, and myocyte hypertrophy. Tissue oxidative stress measured by GSH/GSSG was increased in the heart with increased oxidation product of mitochondrial DNA, 8-oxo-7,8-dihydro-2'-deoxyguanosine, increase of Bax, decrease of Bcl-2, and increase of apoptotic myocytes as measured by anti-single-stranded DNA monoclonal antibody. Administration of carvedilol and metoprolol, which had no effect in sham animals, attenuated cardiac ventricular remodeling, cardiac hypertrophy, oxidative stress, and myocyte apoptosis in CHF. In contrast, propranolol plus doxazosin, which has less antioxidant effects, produced smaller effects on left ventricular function and myocyte apoptosis. In all animals, GSH/GSSG correlated significantly with changes of left ventricular end-diastolic dimension (r = 0.678, P < 0.0001), fractional shortening (r = 0.706, P < 0.0001), and apoptotic myocytes (r = 0.473, P = 0.0001). Thus our findings suggest antioxidant and antiapoptotic actions of carvedilol and metoprolol are important determinants of clinical beneficial effects of
-receptors in the treatment of CHF.
carvedilol; metoprolol; oxidative stress; myocytes apoptosis; myocyte hypertrophy.
This article has been cited by other articles:
![]() |
P. Spallarossa, P. Altieri, S. Garibaldi, G. Ghigliotti, C. Barisione, V. Manca, P. Fabbi, A. Ballestrero, C. Brunelli, and A. Barsotti Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase Cardiovasc Res, February 15, 2006; 69(3): 736 - 745. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Kowey A Review of Carvedilol Arrhythmia Data in Clinical Trials Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S59 - S68. [Abstract] [PDF] |
||||
![]() |
B. Schreiber Levocarnitine and Dialysis: A Review Nutr Clin Pract, April 1, 2005; 20(2): 218 - 243. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |